Dr. Neela Patel is a scientist and business development executive with 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development through external innovation. Prior to Bonum, as Chief Business Development Office at Good Therapeutics she co-led the Roche transaction and spinout of Bonum. Previously, as Executive Director of Corporate Development at Seagen, she played an integral role in deal sourcing and execution of collaborations, licenses and acquisitions to build the pipeline, including agreements with Pieris and FivePrime. Dr. Patel’s sourcing and diligence at AbbVie in resulted in more than twenty five executed deals including collaborations, licensing, and participation in consortia. Dr. Patel spent the first 16 years of her career in drug discovery with positions of increasing responsibility, advancing small molecules and biologics from target ID and validation through IND filing at Poniard Pharmaceuticals, Genentech, SUGEN/Pharmacia, and Roche Bioscience.
Dr. Patel completed her post-doctoral training at the DNAX Research Institute after receiving her PhD in Molecular Biology from UCLA. She graduated Phi Beta Kappa from Stanford with a B.S. in Biology and a B.A. in Humanities with Honors.